TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Behavioral Therapy in Primary Care: Treating the Medically Ill
Brief Summary: The current study seeks to test the effectiveness of a talk-therapy intervention designed to better meet the needs of chronically ill Veterans. This project looks to recruit 450 Veterans with either chronic obstructive pulmonary disease (COPD) or heart failure (HF) who also have symptoms of worry, stress, anxiety, or sadness. Participants will be randomly put into either the talk-therapy intervention or enhanced usual care.

The talk therapy intervention will be provided by VA clinicians in the primary care setting and will consist of 6 core meetings (30-45 minutes in duration) and 2 follow-up telephone meetings. Enhanced usual care participants will receive feedback regarding the assessment findings and educational materials on COPD and/or HF, depression and anxiety.


Options:
A: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: care at initiative of the patient (usual GP care) | Arm Label: monitoring controls; Type: EXPERIMENTAL; Interventions: Behavioral: regular practice nurse review (monitoring controls) | Arm Label: self-management; Type: EXPERIMENTAL; Interventions: Behavioral: an integrated self-management education program | Intervention Type: BEHAVIORAL; Name: an integrated self-management education program; Assigned to Arm(s): self-management | Intervention Type: BEHAVIORAL; Name: regular practice nurse review (monitoring controls); Assigned to Arm(s): monitoring controls | Intervention Type: BEHAVIORAL; Name: care at initiative of the patient (usual GP care); Assigned to Arm(s): usual care
B: Arm Label: Experimental - CPW (Urban); Type: N/A; Interventions: Other: Clinical Pathway (CPW) | Arm Label: Experimental - CPW (Rural); Type: N/A; Interventions: Other: Clinical Pathway (CPW) | Arm Label: Control - Standard Care (Urban); Type: N/A; Interventions: N/A | Arm Label: Control - Standard Care (Rural); Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Pathway (CPW); Assigned to Arm(s): Experimental - CPW (Rural), Experimental - CPW (Urban)
C: Arm Label: ACCESS; Type: EXPERIMENTAL; Interventions: Behavioral: ACCESS | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACCESS; Assigned to Arm(s): ACCESS
D: Arm Label: Health Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health Coaching | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health Coaching; Assigned to Arm(s): Health Coaching

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oxidative Stress in Chronic Kidney Disease: Diet and Exercise
Brief Summary: The central aim of this study is to improve understanding of how metabolic pathways that contribute to adiposity also amplify risks of kidney disease progression and cardiovascular disease in subjects with moderate to severe CKD. In order to achieve this goal, we propose the following aims through a randomized 2x2 factorial design trial in subjects with moderate to severe CKD: (a) To assess the feasibility of implementing aerobic exercise and caloric restriction interventions, and (b) To examine the effects of aerobic exercise and caloric restriction on a metabolic risk profile, including systemic measures of oxidative stress, inflammation, insulin resistance, and endothelial dysfunction.

Hypothesis: We hypothesize that implementation of caloric restriction and aerobic exercise is feasible and can improve the metabolic milieu (as assessed by measures of oxidative stress, inflammation, insulin resistance, and endothelial dysfunction) in subjects with moderate to severe CKD.

Interim analysis may be performed (no specific plan at this time).


Options:
A: Arm Label: Intensive education of low salt diet; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive education of low salt diet | Arm Label: Conventional diet group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive education of low salt diet; Assigned to Arm(s): Intensive education of low salt diet
B: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
C: Arm Label: caloric restriction; Type: ACTIVE_COMPARATOR; Interventions: Other: caloric restriction | Arm Label: aerobic exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: aerobic exercise | Arm Label: caloric restriction and aerobic exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: caloric restriction, Other: aerobic exercise | Arm Label: usual diet and usual activity; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: caloric restriction; Assigned to Arm(s): caloric restriction, caloric restriction and aerobic exercise | Intervention Type: OTHER; Name: aerobic exercise; Assigned to Arm(s): aerobic exercise, caloric restriction and aerobic exercise
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bardoxolone Methyl; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl: 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bardoxolone Methyl: 20 mg; Assigned to Arm(s): Bardoxolone Methyl

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Safety Trial of CTX0E03 Drug Product Delivered Intracranially in the Treatment of Patients With Stable Ischemic Stroke
Brief Summary: The study is designed to test the safety of a manufactured neural stem cell line (CTX cells) delivered by injection into the damaged brains of male patients 60 years of age or over who remain moderately to severely disabled 6 months to 5 years following an ischemic stroke. In addition the trial will evaluate a range of potential efficacy measures for future trials. Treatment will involve a single injection of one of four doses of CTX cells into the patient's brain in a carefully controlled neurosurgical operation performed under general anesthetic. The trial is designed to treat 12 patients and measure outcomes over 24 months. Patients will be invited to participate in a long-term follow-up trial for a further 8 years.


Options:
A: Arm Label: bone marrow stem cells; Type: OTHER; Interventions: Procedure: Infusion on autologous CD34+ stem cells into middle cerebral artery | Intervention Type: PROCEDURE; Name: Infusion on autologous CD34+ stem cells into middle cerebral artery; Assigned to Arm(s): bone marrow stem cells
B: Arm Label: CTX0E03 DP; Type: EXPERIMENTAL; Interventions: Biological: CTX0E03 neural stem cells | Intervention Type: BIOLOGICAL; Name: CTX0E03 neural stem cells; Assigned to Arm(s): CTX0E03 DP
C: Arm Label: Autologous bone marrow stem cell; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow stem cell | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow stem cell; Assigned to Arm(s): Autologous bone marrow stem cell
D: Arm Label: Stem Cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow mononuclear cell transplantation | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow mononuclear cell transplantation; Assigned to Arm(s): Stem Cells

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Proof of Concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Protective Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in Healthy, HIV-infected Adults
Brief Summary: This is a phase II, proof of concept, randomized, double-blind, placebo-controlled study to evaluate the protective efficacy against TB disease, safety, and immunogenicity of MVA85A/AERAS-485 in healthy, HIV-infected adults.

This study consists of 650 adults subjects (ages 18-50 years of age inclusive) who will receive study vaccine or placebo at Study Day 0 and again 6-9 months later. Samples for real-time evaluation of immunogenicity were to be collected from 70 subjects (immunogenicity analysis set).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: BCG | Intervention Type: BIOLOGICAL; Name: BCG; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: FP85A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: FP85A, Biological: MVA85A | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: FP85A, Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: FP85A; Assigned to Arm(s): 1, 2, 3 | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): 2, 3
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: MVA85A/AERAS-485; Type: EXPERIMENTAL; Interventions: Biological: MVA85A/AERAS-485 | Intervention Type: BIOLOGICAL; Name: MVA85A/AERAS-485; Assigned to Arm(s): MVA85A/AERAS-485 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Brief Summary: The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with hypertension (msSBP ≥ 95th percentile for age, gender and height, at baseline in study CSPP100A2365). Patients will be randomized to receive either aliskiren or enalapril. Weight-group based doses of aliskiren or enalapril will be administered once daily and children will receive study medication in a double-blind manner. This study is being conducted to support monotherapy registration of aliskiren for the treatment of hypertension in pediatric patients 6-17 years of age (age at baseline in Study CSPP100A2365).


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Arm Label: Aliskiren-based regimen; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Hydrochlorothiazide, Drug: Amlodipine | Arm Label: Ramipril-based regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Drug: Hydrochlorothiazide, Drug: Amlodipine | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren-based regimen | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril-based regimen | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen
D: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Enalapril

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Multi-centre Placebo Controlled Trial of Dexmedetomidine for Patients With Agitation and Delirium in the Intensive Care Unit
Brief Summary: The primary aim of the DahLIA trial is to determine, in patients with ICU-associated delirium and agitation who are otherwise pathophysiologically stable (as defined), the number of ventilator-free hours in the incident ICU admission in the 7 days following commencement of trial medication, in patients randomised to receive dexmedetomidine or placebo while receiving all other aspects of standard care.

The null hypothesis assumes no difference in the median number of ventilator-free hours in this ICU admission in the following 7 days, between patients receiving dexmedetomidine and placebo for ICU-associated agitation and delirium.


Options:
A: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Saline placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Saline placebo
B: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
C: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
D: Arm Label: PS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized Sedation | Arm Label: PS + DI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized sedation, with daily interruption | Intervention Type: PROCEDURE; Name: Protocolized Sedation; Assigned to Arm(s): PS | Intervention Type: PROCEDURE; Name: Protocolized sedation, with daily interruption; Assigned to Arm(s): PS + DI

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Multi-centre Placebo Controlled Trial of Dexmedetomidine for Patients With Agitation and Delirium in the Intensive Care Unit
Brief Summary: The primary aim of the DahLIA trial is to determine, in patients with ICU-associated delirium and agitation who are otherwise pathophysiologically stable (as defined), the number of ventilator-free hours in the incident ICU admission in the 7 days following commencement of trial medication, in patients randomised to receive dexmedetomidine or placebo while receiving all other aspects of standard care.

The null hypothesis assumes no difference in the median number of ventilator-free hours in this ICU admission in the following 7 days, between patients receiving dexmedetomidine and placebo for ICU-associated agitation and delirium.


Options:
A: Arm Label: quetiapine; Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): quetiapine | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): haloperidol
B: Arm Label: A - placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ziprasidone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): A - placebo
C: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Saline placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Saline placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: an Open Parallel Clinical Trial in HBV-GN Patients
Brief Summary: Lamivudine treatment for HBV-DNA negative HBV-GN patients.


Options:
A: Arm Label: prednisone; Type: N/A; Interventions: N/A | Arm Label: prednisone and anti-virus; Type: N/A; Interventions: N/A
B: Arm Label: Rituximab Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: Cyclosporine Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab Treatment Arm | Intervention Type: DRUG; Name: Cyclosporine; Assigned to Arm(s): Cyclosporine Treatment Arm
C: Arm Label: late intervention; Type: OTHER; Interventions: Drug: Cyclophosphamide and steroids | Arm Label: early intervention; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide and steroids | Intervention Type: DRUG; Name: Cyclophosphamide and steroids; Assigned to Arm(s): early intervention, late intervention
D: Arm Label: active comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin) | Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | Intervention Type: DRUG; Name: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin); Assigned to Arm(s): active comparator | Intervention Type: DRUG; Name: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab); Assigned to Arm(s): experimental

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Point-Of-Care Testing In Danish General Practice: A Randomised Controlled Trial
Brief Summary: The aim of this project is to evaluate the efficacy of electronic reminder letters versus postal reminder letters on general practices adherence to clinical quality guidelines regarding Point Of Care Testing (POCT).


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Reminders and opinion leader generated guidelines +/- leaflets and counselling | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Reminders and opinion leader generated guidelines +/- leaflets and counselling; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
B: Arm Label: Postal reminders; Type: ACTIVE_COMPARATOR; Interventions: Device: Postal reminder letters, Device: Reminder letters | Arm Label: Electronic reminders; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic reminder letters, Device: Reminder letters | Intervention Type: DEVICE; Name: Postal reminder letters; Assigned to Arm(s): Postal reminders | Intervention Type: DEVICE; Name: Electronic reminder letters; Assigned to Arm(s): Electronic reminders | Intervention Type: DEVICE; Name: Reminder letters; Assigned to Arm(s): Electronic reminders, Postal reminders
C: Arm Label: 1- Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 - Automated Mailing; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Mailing | Arm Label: 3 - Automated Mailing Plus Assisted; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Mailing Plus Assisted | Arm Label: 4 - Auto Plus Assisted Plus Navigation; Type: EXPERIMENTAL; Interventions: Behavioral: Auto Plus Assisted Plus Navigation | Intervention Type: BEHAVIORAL; Name: Automated Mailing; Assigned to Arm(s): 2 - Automated Mailing | Intervention Type: BEHAVIORAL; Name: Automated Mailing Plus Assisted; Assigned to Arm(s): 3 - Automated Mailing Plus Assisted | Intervention Type: BEHAVIORAL; Name: Auto Plus Assisted Plus Navigation; Assigned to Arm(s): 4 - Auto Plus Assisted Plus Navigation
D: Arm Label: LTC Osteoporosis Toolkit Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educ sessions & LTC Osteoporosis toolkit; Type: ACTIVE_COMPARATOR; Interventions: Other: Educ sessions & LTC Osteoporosis toolkit | Intervention Type: OTHER; Name: Educ sessions & LTC Osteoporosis toolkit; Assigned to Arm(s): Educ sessions & LTC Osteoporosis toolkit

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Point-Of-Care Testing In Danish General Practice: A Randomised Controlled Trial - Part II
Brief Summary: The aim of this project is to evaluate the efficacy of electronic reminder letters versus none on general practices adherence to clinical quality guidelines regarding Point Of Care Testing (POCT). The investigators hypothesize, that electronic reminder letters may increase adherence.


Options:
A: Arm Label: 1- Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 - Automated Mailing; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Mailing | Arm Label: 3 - Automated Mailing Plus Assisted; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Mailing Plus Assisted | Arm Label: 4 - Auto Plus Assisted Plus Navigation; Type: EXPERIMENTAL; Interventions: Behavioral: Auto Plus Assisted Plus Navigation | Intervention Type: BEHAVIORAL; Name: Automated Mailing; Assigned to Arm(s): 2 - Automated Mailing | Intervention Type: BEHAVIORAL; Name: Automated Mailing Plus Assisted; Assigned to Arm(s): 3 - Automated Mailing Plus Assisted | Intervention Type: BEHAVIORAL; Name: Auto Plus Assisted Plus Navigation; Assigned to Arm(s): 4 - Auto Plus Assisted Plus Navigation
B: Arm Label: reminders, no reminder; Type: EXPERIMENTAL; Interventions: Behavioral: reminders vs. no reminders | Intervention Type: BEHAVIORAL; Name: reminders vs. no reminders; Assigned to Arm(s): reminders, no reminder
C: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
D: Arm Label: Electronic reminders; Type: ACTIVE_COMPARATOR; Interventions: Device: Electronic reminder letters | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic reminder letters; Assigned to Arm(s): Electronic reminders

Answer: D